BeOne Medicines Ltd. SEC filings ONC
BeOne Medicines Ltd. has 1,002 filings in SEC EDGAR's recent list, going back to Nov 19, 2018. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| UPLOAD | Letter from the SEC | Jun 18, 2025 | — |
| CORRESP | Letter to the SEC | Jun 10, 2025 | — |
| EFFECT | Filing | Jun 2, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 2, 2025 | — |
| POSASR | Filing | May 27, 2025 | — |
| POSASR | Filing | May 27, 2025 | — |
| 8-K12G3 | Form 8-k12g3 | May 27, 2025 | May 27, 2025 |
| EFFECT | Filing | May 23, 2025 | — |
| EFFECT | Filing | Mar 7, 2025 | — |
| CORRESP | Letter to the SEC | Mar 6, 2025 | — |
| CORRESP | Letter to the SEC | Feb 27, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 31, 2025 | — |
| CORRESP | Letter to the SEC | Jan 21, 2025 | — |
| CORRESP | Letter to the SEC | Oct 24, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 18, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 5, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 3, 2024 | — |
| CORRESP | Letter to the SEC | Aug 21, 2024 | — |
| CORRESP | Letter to the SEC | Jul 31, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 25, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 7, 2023 | — |
| CORRESP | Letter to the SEC | Oct 4, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 21, 2023 | — |
| CORRESP | Letter to the SEC | Aug 21, 2023 | — |
| CORRESP | Letter to the SEC | Jul 26, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 21, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 15, 2022 | — |
| CORRESP | Letter to the SEC | Jun 3, 2022 | — |
| UPLOAD | Letter from the SEC | May 20, 2022 | — |
| CORRESP | Letter to the SEC | May 6, 2022 | — |
| CORRESP | Letter to the SEC | Apr 11, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 7, 2022 | — |
| UPLOAD | Letter from the SEC | Jan 28, 2022 | — |
| CORRESP | Letter to the SEC | Dec 17, 2021 | — |
| CORRESP | Letter to the SEC | Nov 24, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 22, 2021 | — |
| CORRESP | Letter to the SEC | Oct 29, 2021 | — |
| CORRESP | Letter to the SEC | Sep 30, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 21, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 19, 2021 | — |
| CORRESP | Letter to the SEC | Apr 13, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 23, 2021 | — |
| PRER14A | Filing | Sep 28, 2020 | — |
| POSASR | Filing | May 9, 2019 | — |
Showing 44 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ONC (Nasdaq), BEIGF (OTC)
- Fiscal year ends
- December 31
- Headquarters
- Basel
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1651308
- Former names
- BeiGene, Ltd. (until May 27, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.